Key facts
- It has raised $80K; the latest was Later Stage VC in May 2025.
- Notable investors include US National Science Foundation, National Institutes of Health, VentureWell, Advance Ventures, BioTN Foundation — 7 tracked in total.
- NeuroDyne has filed 2 Form Ds with the SEC, most recently Oct 2022 ($75K sold to 2 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for NeuroDyne
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroDyne are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroDyne
Developer of medical technology designed for the diagnosis and treatment of neurological diseases. The company's technology develops neurological devices that alleviate seizure activity in children who suffer from congenital brain disease, adult seizure activity, and veterans who suffer from brain damage, enabling medical professionals to ensure relief for those who suffer from debilitating seizure effects.
- Sector
- Healthcare
- HQ
- Germantown, TN, United States
- Founded
- 2005
- Website
- neurodyneinc.com/
- Ownership
- Privately Held (backing)
NeuroDyne doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroDyne shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroDyne in its N-PORT filings yet. We sweep new filings monthly.